Farris Partner Hector MacKay-Dunn, Q.C. extends the Firm’s congratulations to Celator Pharmaceuticals, Ewing, N.J./Vancouver, B.C. and Jazz Pharmaceuticals, Dublin on the announcement of Jazz Pharmaceuticals acquiring Celator for USD $1.5 billion. Celator is a clinical stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator’s lead product is VYXEOS, a therapy that has completed a Phase 3 trial for the treatment acute myeloid leukemia and aims to treat AML with two currently available drugs in a new formulation.
Celator has strong roots to Vancouver, B.C. as the first spin-out of the British Columbia Cancer Agency, the brain child of founders Drs. Lawrence Mayer and Marcel Bally, and developed under the leadership of Dr. Lawrence Mayer, President and Chief Scientific Officer. Dr. Mayer played a lead role in the discovery and development of anti cancer drugs. Hector MacKay-Dunn, J.D., Q.C. and the Farris biotech group represented Celator in its formation on the spin out transaction and continued as advisor in its early development supporting Celator’s growth from start up through to development stage.